Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-186 in Unresectable Locally Advanced or Metastatic Cancer
NCT04844073Phase 2Terminated
- Sponsor
- Takeda
- Start
- Mar 2021
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of TAK-186 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Takeda. Started Mar 2021; status: terminated.
02
Drugs
TAK-186
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04844073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844073.